Sugi Predict

Sugi Predict / Compounds / SCHEMBL5033775

SCHEMBL5033775

SCHEMBL5033775

CC(C)(C)OC(=O)N[C@H](CC(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 3/20 0.58
▸ KLK7 P49862 1/20 0.55
▸ KLK5 Q9Y337 1/20 0.55
▸ SYK P43405 1/20 0.55
▸ CTSS P25774 4/20 0.55
▸ CACNA1B Q00975 4/20 0.54
▸ CTSK P43235 3/20 0.53
▸ CASP1 P29466 3/20 0.53
▸ CTSL P07711 1/20 0.53
▸ CTSB P07858 1/20 0.53
▸ PPARG P37231 2/20 0.53
▸ TACR1 P25103 1/20 0.52
▸ ACE P12821 1/20 0.51
▸ MAPT P10636 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1093029 1.00 PPARA (0.58) PPARAKLK7KLK5SYKCTSS
SCHEMBL3004720 1.00 PPARA (0.58) PPARAKLK7KLK5SYKCTSS
SCHEMBL1674845 0.95 PPARA (0.54) PPARAKLK7KLK5SYKCTSS
SCHEMBL14211452 0.91 PPARA (0.57) PPARAKLK7KLK5SYKCTSS
SCHEMBL4370045 0.91 KLK5 (0.65) PPARAKLK7KLK5SYKCTSS
SCHEMBL20144655 0.90 CACNA1B (0.59) PPARAKLK7KLK5SYKCTSS
SCHEMBL20481004 0.90 CACNA1B (0.59) PPARAKLK7KLK5SYKCTSS
SCHEMBL7965696 0.90 PPARA (0.56) PPARAKLK7KLK5SYKCTSS
SCHEMBL7297130 0.90 PPARA (0.56) PPARAKLK7KLK5SYKCTSS
SCHEMBL16286010 0.90 CACNA1B (0.59) PPARAKLK7KLK5SYKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
EP-4628163-A1 NOVEL HETEROARYL AMINOPROPANOL DERIVATIVES Novartis AG (CH) 2025-10-08 — — EP disclosed
US-12415796-B2 Inhibitors of (αv)(β6) integrin MORPHIC THERAPEUTIC, INC. (US) 2025-09-16 — — US disclosed
EP-4323062-B1 HETEROARYL AMINOPROPANOL DERIVATIVES AS INHIBITORS OF LTA4H NOVARTIS AG (CH) 2025-07-23 — — EP disclosed
CN-119775260-A Pyrimidine-2, 4 (1H, 3H) -dione compounds, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2025-04-08 — — CN disclosed
US-20250059213-A1 LONP1 INHIBITORS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-02-20 — — US disclosed
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-02-20 — — US disclosed
CN-119176804-A Amidopyrroles and application thereof in medicines 广东东阳光药业股份有限公司 2024-12-24 — — CN disclosed
US-12173018-B2 Penicillin-binding protein inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2024-12-24 — — US disclosed
EP-4444726-A1 LONP1 INHIBITORS, USES AND METHODS Pretzel Therapeutics, Inc. (US) 2024-10-16 — — EP disclosed
WO-2018160521-A2 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. (US) 2018-09-07 — — WO disclosed
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2018-08-30 — — US disclosed
US-9920044-B2 Selective androgen receptor modulators RADIUS PHARMACEUTICALS, INC. (US) 2018-03-20 — — US disclosed
US-7786163-B2 Constrained cyano compounds Forest Laboratories Holdings Limited (BM) 2010-08-31 — — US disclosed
EP-1918278-A1 Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases Novartis AG (CH) 2008-05-07 — — EP disclosed
US-20070129371-A1 Novel ethylenediamine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-06-07 — — US disclosed
EP-1577302-A1 NOVEL ETHYLENEDIAMINE DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-09-21 — — EP disclosed
US-6410580-B1 ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES NOVARTIS AG (CH) 2002-06-25 — — US disclosed
US-6277987-B1 FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS NOVARTIS AG (CH) 2001-08-21 — — US disclosed
WO-2000055156-A1 SUBSTITUTED AROMATIC AMIDINE DERIVATIVE AND MEDICINAL COMPOSITION COMPRISING THE SAME C & C RESEARCH LABORATORIES (KR) 2000-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129371-A1 Novel ethylenediamine derivatives C1R, C9, C1S PPARA 3626/4885KLK7 4271/4885KLK5 4138/4885
US-12415796-B2 Inhibitors of (αv)(β6) integrin ITGB6, ITGA6, ITGAV PPARA 3899/4885KLK7 1555/4885KLK5 2261/4885
US-20250059213-A1 LONP1 INHIBITORS, USES AND METHODS LONP1, ACAT1, ACAA2 PPARA 2373/4885KLK7 4039/4885KLK5 3609/4885
US-12173018-B2 Penicillin-binding protein inhibitors PEPD, BPGM, EBPL PPARA 3280/4885KLK7 3693/4885KLK5 3315/4885
US-20180244648-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV PPARA 3350/4885KLK7 1767/4885KLK5 2204/4885
US-20250059214-A1 AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, ACAT1, ACAA2 PPARA 1372/4885KLK7 4446/4885KLK5 4114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.